Board of Directors
Acting in the interest of shareholders by setting high standards for employees, directors and management of the Company’s business
Sacha Loiseau, Ph.D
Founder, Chairman of the Board and CEO
SACHA FOUNDED MAUNA KEA TECHNOLOGIES IN 2000
Sacha is the co-inventor of the probe-based Confocal Laser Endomicroscopy technology and conducted the development of the Cellvizio product line, raising over €120m with private and public investors, including €56.5m through an IPO in July 2011 on the NYSE Euronext Paris stock exchange. In 2013, Sacha was named co-lead of France’s Re-industrialization Plan for Medical Devices by the French President and then a member of the Committee for the Future of Medicine. Sacha has served as a mentor of the Polytechnique-Stanford Ignite Program for young MedTech entrepreneurs for several years. Sacha was instrumental in the foundation of the association Medtech in France, of which he is Vice-President.
Sacha started his career at the National Center for Space Studies (CNES) in Toulouse and at the Paris Observatory, then joined NASA’s Jet Propulsion Laboratory (JPL) in Pasadena, California, as a research scientist. Sacha is a graduate of Ecole Polytechnique and holds a Ph.D. in Astrophysics and Optical Instrumentation from University Paris-Diderot. He is the author of multiple scientific papers and holds 7 international patents and was the 2018 recipient of the Marius Lavet Prize.
Christopher D. McFadden, CFA
Member of the Board
Chair of the compensation and nomination committee
MANAGING DIRECTOR AT APOLLO GLOBAL MANAGEMENT
Molly O’Neill
Member of the Board
EXPERIENCED GLOBAL HEALTHCARE GROWTH AND STRATEGY EXECUTIVE
Molly O’Neill brings over 30 years of experience developing growth strategies to increase market share and revenue of P/E backed, public company, academic, and not-for-profit health care organizations. She is a recognized leader at some of the world’s most prestigious healthcare delivery systems with ground- breaking product development achievements in medical education, medical devices and digital health.
Currently, Ms. O’Neill serves as the Chief Strategic Partnerships Officer for Aegis Ventures, a next-generation venture studio that partners with leading health systems, entrepreneurs and industry leaders to originate, launch, and scale transformative companies. She has led strategy and business development as a Vice Chancellor of Duke Medicine, Executive Director of Specialty Care for Mass General Brigham and provided national growth leadership at Tenet Healthcare, Ascension Health Care Network and Inova Health System.
Elsy Boglioli Hofman
Member of the Board
STRATEGIC ADVISOR AND SENIOR LIFE SCIENCES EXECUTIVE
A recognized expert in the healthcare and biotechnology sectors, Elsy Boglioli Hofman has led Bio-Up, a strategic advisory firm for HealthTech leaders, since 2019. Her professional background includes high-level executive roles, notably as Chief Operating Officer of Cellectis and Partner & Managing Director at the Boston Consulting Group (BCG). An experienced board member, she currently serves as an Independent Director for FTI Consulting (NYSE) and GenSight Biologics (Euronext) and chairs the Board of TreeFrog Therapeutics. She is a graduate of École Polytechnique.
Richard Di Benedetto
Member of the Board
GLOBAL MEDTECH LEADER
A globally recognized leader in the healthcare sector, Richard Di Benedetto brings extensive executive experience from world-leading organizations. He currently serves as Chairman of Alliance Medical Group and Chairman of the Board of T2S Group, while also holding a Non-Executive Director position at Vanguard Healthcare Solutions. His distinguished career is highlighted by his decade-long tenure as President of Aetna International (CVS Health group), overseeing global health benefits, and as CEO of Euromedic International. He also spent 15 years at GE Healthcare in various senior roles, including President and CEO for the Middle East, Africa, and Russia regions. An expert in global growth strategies, he holds a Master’s degree in Economics from the Institut d’Études Politiques de Paris. Richard Di Benedetto holds 1,027,749 shares of Mauna Kea Technologies from the November 2025 capital increase.
Randall Stanicky
Member of the Board
U.S. CAPITAL MARKETS AND CORPORATE FINANCE EXECUTIVE
A recognized expert in financing medical innovation, Randall Stanicky brings over 20 years of Wall Street experience. He currently serves as Chief Financial Officer of Click Therapeutics, where he has successfully led several debt and equity fundraising rounds. His professional background includes high-level executive roles with leading global investment banks, with most of his sell-side career spent at Goldman Sachs. An experienced board member, he currently serves on the boards of Cellphire Therapeutics and Children’s Tumor Foundation (Honorary), and previously served on the board of TherapeuticsMD. He holds a Bachelor of Commerce from the University of British Columbia (UBC).
News
YOU MIGHT ALSO LIKE TO READ
Mauna Kea Technologies Announces the Results of its Combined General Meeting of June 4, 2026
Mauna Kea Technologies Announces New Publication in the UEG Journal Identifying “Triple Healing”, a Cellvizio®— Assessed Therapeutic Target Associated with Sustained Remission in Ulcerative Colitis
Mauna Kea Technologies Expands Presence in the Middle East with UAE and Turkey Regulatory Approvals and First CellTolerance® Commercial Installation
Find out more by downloading the
Cellvizio Brochure